Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin.
We have investigated changes in the pharmacokinetics of prednisolone caused by co-administration or discontinuation of rifampin. Serial IV pharmacokinetic studies of prednisolone (1 mg/kg) in groups of 3 patients over a 1 month period of rifampin co-treatment or after its withdrawal, revealed significant changes in the area under the curve, the total clearance, the non-renal clearance and the half-life. The changes in the pharmacokinetic parameters reached a 1.5 to 2-fold plateau after 2 weeks and the half maximal effect was attained within 5 days. Neither the volume of distribution nor the protein binding of prednisolone were significantly altered.
Lee
K H
KH
Department of Pharmacology, Clinical Pharmacology, Seoul National University College of Medicine, Korea.
Shin
J G
JG
Chong
W S
WS
Kim
S
S
Lee
J S
JS
Jang
I J
IJ
Shin
S G
SG
D000328:Adult; D004347:Drug Interactions; D005260:Female; D006207:Half-Life; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000378:metabolism; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000378:metabolism; D011239:Prednisolone / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D011485:Protein Binding; D012293:Rifampin / Q000008:administration & dosage* / Q000494:pharmacology; D013997:Time Factors
D011239:Prednisolone; D012293:Rifampin